CARsgen Therapeutics forecasts 77% loss reduction for H1 2025
CARsgen Therapeutics expects its net loss to fall to no more than RMB80 million for the six months ended June 30, 2025, down from RMB351 million in the same period of 2024.
Adjusted net loss is projected at no more than RMB75 million, down from RMB342 million previously. The improvement is driven by increased revenues from commercializing CT053 in mainland China, favorable foreign exchange movements, and reduced research and development spending on CT053 and CT041.
The New Drug Application for CT041 has been accepted by the NMPA.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when CARsgen Therapeutics publishes news
Free account required • Unsubscribe anytime